Atif Zaman, MD, MPH
Consulting Editor, Hepatology
NEJM Journal Watch General Medicine
About the NEJM Journal Watch General Medicine Board
Atif Zaman, MD, MPH, is Professor in the Department of Gastroenterology and Hepatology at Oregon Health & Science University, Portland, where he is also the Senior Associate Dean for Clinical and Faculty Affairs in the School of Medicine and Senior Vice President and Chief Clinical Officer of OHSU Health. Dr. Zaman's research includes many projects in hepatology. He is the recipient of the WAFMR Outstanding Investigator Award. Dr. Zaman is a member of several national societies: the American Gastroenterology Association, the American College of Physicians, and the American Association for the Study of Liver Diseases. He has presented more than 25 lectures and authored more than 50 manuscripts, review articles, and abstracts. Dr. Zaman reviewed hepatology literature for NEJM Journal Watch Gastroenterology from 2004 until the publication's closure in 2020, and has been a Consulting Editor for NEJM Journal Watch General Medicine since 2020.
Dr. Zaman has no disclosures.
Summaries by Atif Zaman
Atif Zaman, MD, MPH, reviewing Bhattacharya D et al. Clin Infect Dis 2023 May 25
A joint guideline from two professional societies updates a 2020 recommendation statement.
Atif Zaman, MD, MPH, reviewing Chalasani NP et al. Am J Gastroenterol 2021 May 1
The American College of Gastroenterology has updated its 2014 practice guideline.
Atif Zaman, MD, MPH, reviewing Siddiqui MS et al. Clin Gastroenterol Hepatol 2020 Nov 2
Pilot study data show promise of histological efficacy.
Atif Zaman, MD, MPH, reviewing Deneau MR. Hepatology 2020 Sep 18
Oral vancomycin is not effective in this setting.
Atif Zaman, MD, MPH, reviewing Sarkar M et al. Clin Gastroenterol Hepatol 2020 Sep 30
Risks for NASH and fibrosis rose with increasing free T level in premenopausal women, but only in the youngest quartile.
Atif Zaman, MD, MPH, reviewing de Vries E et al. Gastroenterology 2020 Oct 5
Bezafibrate was superior to placebo in reducing pruritus intensity in the short term.
Atif Zaman, MD, MPH, reviewing Beste LA et al. JAMA 2020 Sep 8
Time trend analyses support the hypothesis that HCV eradication reduces the incidence of hepatocellular carcinoma.
Atif Zaman, MD, MPH, reviewing Rohde MD et al. Clin Gastroenterol Hepatol 2020 Aug 21
Risk for VZV reactivation was not greater with DAAs than with placebo.
Atif Zaman, MD, MPH, reviewing Kaplan DE et al. Clin Gastroenterol Hepatol 2020 Aug 12
Metformin use was associated with lower overall mortality but not with improved liver-related outcomes.
Atif Zaman, MD, MPH, reviewing Kim D et al. Clin Gastroenterol Hepatol 2020 Jul 16
Findings are strengthened by objective measurement of physical activity using accelerometers.
Atif Zaman, MD, MPH, reviewing Kuriry H et al. Clin Gastroenterol Hepatol 2020 Jul 3
Spontaneous viral clearance seems to occur in about 10% of patients.
Atif Zaman, MD, MPH, reviewing Semmler G et al. Hepatology 2020 Jul 13
Following successful HCV treatment, two easily obtained clinical measures predict hepatic decompensation in patients with advanced liver fibrosis.
Atif Zaman, MD, MPH, reviewing Petta S et al. Clin Gastroenterol Hepatol 2020 Jul 1
Retrospective study findings suggest utility in predicting liver-related complications and survival but require validation.
Atif Zaman, MD, MPH, reviewing Kim SW et al. Clin Gastroenterol Hepatol 2020 Jul 2
Empiric use of carbapenem was not associated with reduced in-hospital mortality, except in a subgroup with severe liver disease.
Atif Zaman, MD, MPH, reviewing Reig A et al. Am J Gastroenterol 2020 May 27
Anti-HK1 and anti-KLHL12 are useful in diagnosing PBC in the absence of antimitochondrial antibodies, and anti-HK1 appears prognostic.
